Symbols

ABSI

Absci·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

RSI Overbought

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABSI

Absci Corporation

A drug and target discovery company that harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins

Industry

Biological Technology

Established Date

Listing Date

07/22/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

157

Fiscal Year Ends

12-31

Website

www.absci.com

Security Type

Common stock

Office address

18105 SE Mill Plain Blvd, Vancouver, WA 98683

Business

Introduction

Absci Corporation was incorporated as a limited liability company in Oregon in August 2011. The company is a data-first generative AI drug creation company that combines AI with scalable wet laboratory technology to create better biologics for patients at a faster rate.

Earnings Call

Q1/2025

Estimate EPS-0.22

Actual EPS-0.21

Estimate Revenue1.07M

Actual Revenue1.18M

Absci's Q1 2025: Key Contradictions in Pipeline Development and Partnership Strategy

May 20,2025 03:44·
Earnings Decrypt

Q2/2025

Estimate EPS-0.21

Actual EPS-0.24

Estimate Revenue1.35M

Actual Revenue600.00K

Absci's Q2 2025 Earnings Call: Unraveling Key Contradictions in Revenue Recognition, Dosing Strategies, and Clinical Timelines

Aug 13,2025 12:30·
Earnings Decrypt

Company Financials

EPS

ABSI has released its 2025 Q3 earnings. EPS was reported at -0.2, versus the expected -0.21, beating expectations. The chart below visualizes how ABSI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ABSI has released its 2025 Q3 earnings report, with revenue of 378.00K, reflecting a YoY change of -77.78%, and net profit of -28.71M, showing a YoY change of -4.77%. The Sankey diagram below clearly presents ABSI's revenue sources and cost distribution.